Characterization of human cardiac Kv1.5 inhibition by the novel atrial-selective antiarrhythmic compound AVE1231.

@article{Ehrlich2008CharacterizationOH,
  title={Characterization of human cardiac Kv1.5 inhibition by the novel atrial-selective antiarrhythmic compound AVE1231.},
  author={Joachim R. Ehrlich and Hellen Ocholla and Daniel Ziemek and Hartmut Ruetten and Stefan H. Hohnloser and Heinz Goegelein},
  journal={Journal of cardiovascular pharmacology},
  year={2008},
  volume={51 4},
  pages={380-7}
}
OBJECTIVE Atrial-selective drug therapy represents a novel therapeutic approach for atrial fibrillation management. The aim of the present study was to investigate the mechanism of hKv1.5 channel inhibition by the atrial-selective compound AVE1231. METHODS Ionic currents were recorded from CHO cells transfected with KCNA5 cDNA with whole-cell patch-clamp technique. The effect of AVE1231 on human atrial cell action potentials was explored with a computer model. RESULTS KCNA5 expression… CONTINUE READING

From This Paper

Topics from this paper.
4 Citations
0 References
Similar Papers

Similar Papers

Loading similar papers…